260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP
Blue Owl Capital Holdings LP recently acquired 260,000 shares of Viridian Therapeutics, Inc. (VRDN) valued at approximately $4.8 million, making it their 23rd largest holding. Despite a recent quarterly loss, the company exceeded revenue expectations, and analysts maintain a "Moderate Buy" consensus with an average price target of $38.93. Insider activity also noted a sale of shares by Jennifer Tousignant.
Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing
Deep Track Capital, LP has reduced its stake in Viridian Therapeutics Inc (VRDN) by 33.68%, selling over 1.8 million shares. This rebalancing act leaves the investment firm with a 1.08% portfolio allocation to VRDN, a clinical-stage biotechnology company focused on thyroid eye disease. Despite the reduction, Deep Track Capital maintains some confidence in Viridian's long-term prospects, even as the stock experiences volatility and financial metrics indicate challenges typical of early-stage biopharmaceutical companies.
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares
Jennifer Tousignant, Chief Legal Officer at Viridian Therapeutics, sold 14,212 company shares for a total of $348,194 on August 19, 2026, at $24.50 per share. This transaction followed her acquisition of 10,000 shares through stock options at a lower exercise price. The sales occurred as VRDN shares experienced a gain and shortly after the company received FDA approval for its thyroid eye disease treatment, Lumvoa, leading to positive analyst outlooks.
Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares
Jennifer Tousignant, an insider at Viridian Therapeutics (NASDAQ:VRDN), sold 14,212 shares of the company's stock for a total of $348,194. This transaction occurred on August 19th, as disclosed in an SEC filing. Despite the insider sale, analysts maintain a "Moderate Buy" consensus rating for VRDN with an average price target of $38.93, even after the company reported a slight earnings per share miss but exceeded revenue estimates in its latest quarterly results.
Viridian Therapeutics (VRDN) legal chief sells 14,212 shares
Jennifer Tousignant, Chief Legal Officer of Viridian Therapeutics, Inc. (VRDN), exercised stock options to acquire 10,000 shares and subsequently sold a total of 14,212 shares of common stock at $24.50 per share on August 19, 2026. This transaction included 718 shares previously obtained through the company's Employee Stock Purchase Plan. Following these actions, Tousignant still holds 114,072 outstanding option shares from a grant dated March 3, 2025.
Steven Cohen’s Point72 discloses Viridian stake (VRDN)
Steven Cohen's Point72 Asset Management, along with Point72 Capital Advisors, Inc., and Steven A. Cohen, has disclosed a 5.0% beneficial ownership stake in Viridian Therapeutics, Inc. (VRDN). This stake, totaling 5,687,507 shares, is held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. The entities report shared voting and dispositive power over these shares, as detailed in a recent SCHEDULE 13G SEC filing.
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers
Viridian Therapeutics (VRDN) recently reported Q2 2026 earnings, showing increased revenue but continued net losses. Despite the company being flagged as trading at an 83% discount to its SWS DCF fair value estimate of $140.56, its Price-to-Sales (P/S) ratio of 38.1x is considered expensive compared to industry averages. Investors are presented with conflicting signals regarding its valuation, emphasizing the need for personal due diligence.
ETFs Investing in Viridian Therapeutics, Inc. Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Viridian Therapeutics, Inc. (1S1) stocks, sorted by market value. It details various ETFs, including their market value, weight of Viridian stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information helps investors understand how different ETFs offer exposure to Viridian Therapeutics with varying risk profiles and investment strategies.
Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN
Handelsbanken Fonder AB has invested $834,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by acquiring 45,400 shares in the second quarter. The company maintains a "Moderate Buy" consensus rating from analysts with an average target price of $38.93, despite a recent quarterly loss of $1.05 per share. Viridian Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapies for rare diseases like thyroid eye disease.
Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026
An officer at Viridian Therapeutics, Inc. (VRDN), Jennifer Tousignant, plans to sell 14,212 shares of common stock valued at $348,194.00 around August 19, 2026. This sale is being made under Rule 144 and comprises shares obtained through restricted stock vesting, an ESPP purchase, and a stock option exercise. The filing indicates a neutral impact and sentiment for Viridian Therapeutics.
GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN
GSA Capital Partners LLP invested $903,000 in Viridian Therapeutics (NASDAQ:VRDN) by acquiring 49,177 shares during the second quarter. The article highlights other institutional investments, Viridian's recent earnings report (missing EPS but beating revenue estimates), and generally positive analyst sentiment with a "Moderate Buy" consensus rating and an average price target of $38.93. Viridian Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics for rare and serious diseases.
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers
Viridian Therapeutics (VRDN) recently released its Q2 2026 earnings, showing increased revenue but also widening losses. While the company's stock has seen recent positive momentum, its Price-to-Sales (P/S) ratio of 38.1x is significantly higher than industry averages, suggesting it is overvalued on this metric. However, a Discounted Cash Flow (DCF) model indicates the stock could be 83% undervalued, trading at $23.93 against an estimated fair value of $140.56, highlighting mixed signals for investors.
Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option
Viridian Therapeutics, Inc. (VRDN) Chief Medical Officer, Radhika Tripuraneni, acquired 40,000 shares of common stock by exercising a stock option at $13.21 per share on August 14, 2026. This transaction increased her direct common stock holdings to 40,000 shares, with no derivative shares remaining from the exercised option. The option was fully vested and had an expiration date of July 1, 2034.
1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC has acquired a new stake of 1,175,906 shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) worth approximately $21.6 million, making it their 29th-largest portfolio holding. Despite the company reporting a quarterly EPS loss that narrowly missed analyst expectations, Viridian shares traded up 4.6% to $23.09. Analyst sentiment for VRDN remains favorable, with a "Moderate Buy" consensus and an average price target of $38.93.
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.
Merck & Co. Inc. recently acquired 93,414 shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the second quarter, representing 0.09% of Viridian’s outstanding stock and valued at approximately $1.716 billion. This acquisition highlights increased institutional interest in Viridian, with other major investors like Perceptive Advisors and Vanguard also boosting their stakes. Despite missing recent quarterly earnings expectations with an adjusted loss of $1.05 per share, analysts maintain a "Moderate Buy" consensus for VRDN with an average price target of $38.93.
Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN
Bank of America Corp DE significantly increased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 17.5% in the first quarter, purchasing an additional 173,498 shares and now holding over 1.16 million shares valued at approximately $22.8 million. Despite Viridian Therapeutics reporting a quarterly loss that missed analyst expectations, its shares rose 4.6% to $23.09. Wall Street analysts maintain a broadly optimistic outlook, with a consensus "Moderate Buy" rating and a price target of $38.93.
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G
T. Rowe Price Associates, Inc. has disclosed a 5.2% beneficial ownership stake in Viridian Therapeutics, Inc. (VRDN) through a Schedule 13G SEC filing. As of June 30, 2026, the firm holds 5,748,426 shares of common stock, with sole voting power over 5,748,380 shares and sole dispositive power over all 5,748,426 shares. The filing indicates a passive investment, with T. Rowe Price Associates denying beneficial ownership despite its reported holdings.
Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund
Paradigm BioCapital Advisors LP, its general partner, and Senai Asefaw M.D. have reported a beneficial ownership of 6,723,788 shares of Viridian Therapeutics (VRDN) common stock, representing 6.1% of the outstanding class as of June 30, 2026. Separately, Paradigm BioCapital International Fund Ltd. directly holds 5,896,154 shares, or 5.3% of the class. The ownership percentages are based on 110,427,682 shares outstanding as of May 11, 2026.
Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported a 3.25% ownership stake in Viridian Therapeutics (VRDN). This ownership, totaling 3,592,740 shares, is held with shared voting and dispositive power. The filing is based on 110,427,682 shares outstanding as of May 8, 2026, with the ownership information current as of June 30, 2026.
Trading the Move, Not the Narrative: (VRDN) Edition
This article provides an AI-generated analysis for Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting mixed sentiment and choppy conditions across different time horizons. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with multi-timeframe signal analysis and support/resistance levels.
Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside
The average 12-month price target for Viridian Therapeutics, Inc. (VRDN) stock has been lowered to $36.07 from $36.81 by 15 analysts, suggesting a potential upside of approximately 58% from its August 12 closing price. Despite the target cut, the consensus rating from 17 covering analysts remains a "Buy," with no "Holds" or "Sells."
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22%
Analysts have significantly cut Viridian Therapeutics, Inc.'s revenue estimates for 2026 by 22% to US$22 million, representing a 70% reduction from the previous year, and increased loss per share forecasts to US$3.97. Despite this downgrade, the stock price recently rose by 10%, indicating investor optimism. The consensus price target remained unchanged, suggesting that the business performance is broadly in line with expectations despite the lower earnings outlook.
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22%
Analysts have significantly revised down Viridian Therapeutics' 2026 revenue estimates by 22% to US$22 million, representing a 70% reduction from the past 12 months. Concurrently, per-share loss forecasts have increased to US$3.97. Despite a recent 10% stock price increase, the updated consensus suggests a more cautious outlook for the company's financial performance.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Have Been Cutting Their Estimates
This article discusses Viridian Therapeutics, Inc. (NASDAQ:VRDN) after its recent earnings report, noting that analysts have begun cutting their estimates for the company. It will likely cover the implications of these revised forecasts on the stock's future performance and investor sentiment. The content will analyze the reasons behind the lowered expectations and what it means for Viridian's financial outlook.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Viridian Therapeutics (NASDAQ:VRDN) recently reported quarterly results showing revenues significantly better than expected, though statutory losses per share were in line with forecasts. Despite the strong revenue performance, analysts have subsequently cut their revenue outlook for 2026 and increased their loss per share expectations, indicating a darker forecast. The consensus price target remained steady at US$36.63, but the revised estimates suggest the company's performance is expected to be substantially worse than the wider industry.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Viridian Therapeutics' latest quarterly results showed revenues significantly exceeding expectations, though statutory losses per share were in line with forecasts. Despite the revenue beat, analysts have revised their 2026 forecasts downward, cutting revenue outlook and increasing loss per share expectations for the company. The consensus price target remained steady, but the updated forecasts suggest a gloomier outlook for Viridian Therapeutics, with projected revenue decline and increased losses, performing worse than the wider industry.
Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN
Renaissance Technologies LLC has acquired a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN), purchasing 203,100 shares valued at approximately $3.97 million. This move is part of broader institutional investor interest, with other firms also modifying their holdings. Despite Viridian Therapeutics missing its latest earnings estimate and posting losses, analysts generally maintain a "Moderate Buy" rating with a consensus price target of $38.93, significantly higher than its current stock price of $23.59.
RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating
RBC has increased its price target for Viridian Therapeutics (VRDN) to $36 from $35, while reiterating an Outperform Speculative Risk rating. The company currently holds an average analyst rating of "buy" with a mean price target of $36.75.
State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership
State Street Corporation has reported a 5.5% ownership stake in Viridian Therapeutics, Inc. (VRDN), held through various subsidiaries including State Street Global Advisors entities. This significant holding comprises 6,124,976 shares of common stock, with shared voting and dispositive power, indicating a notable institutional position in the company. The disclosure was made via a SCHEDULE 13G SEC filing.
Viridian Therapeutics 2Q 2026: Revenue $284K, EPS $(1.05) — 10-Q Summary
Viridian Therapeutics reported its second-quarter 2026 results, showing early commercial revenue of $284K following FDA approval of Veligrotug (Lumvoa). The company experienced a wider net loss of $127.1M, reflecting its transition from an R&D to a commercial organization. Key highlights include the U.S. launch of Veligrotug, positive Phase 3 clinical trial results, and plans for pipeline expansion and a shift towards product sales.
Viridian Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Viridian Therapeutics Inc has released its earnings summary for the quarter that concluded on June 30. The report details the company's financial performance during this period, providing key insights into its operational results. This information is available through Refinitiv, with additional access offered via TradingView.
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
RBC Capital Markets forecasts "minimal" revenue growth for Viridian Therapeutics (VRDN) in the second half of the year. The report, published by MT Newswires, indicates that a more meaningful inflection in revenue is expected after this period. Access to the full article requires a premium Yahoo Finance subscription.
Press Release: Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Viridian Therapeutics has released its second quarter 2026 financial results, alongside an update on recent business developments. This announcement provides insights into the company's financial performance and strategic progress during the quarter.
Viridian Therapeutics reports Q2 2026 net loss of $127.1M, cash $981.5M after Lumvoa FDA approval
Viridian Therapeutics reported a Q2 2026 net loss of $127.1 million, with $981.5 million in cash, cash equivalents, and marketable securities. This report follows the FDA approval and U.S. commercial launch of Lumvoa for thyroid eye disease on June 26, 2026, and the company is on track for an elegrobart BLA submission in Q1 2027. The company also highlighted significant R&D and SG&A expenses, successful early commercial launch activities for Lumvoa, and pipeline progress for other treatments.
First Trust Advisors LP Grows Stock Holdings in Viridian Therapeutics, Inc. $VRDN
First Trust Advisors LP significantly increased its stake in Viridian Therapeutics (NASDAQ:VRDN) by 151.5% in the first quarter, now holding 301,529 shares valued at $5.9 million. The clinical-stage biopharmaceutical company, which develops antibody therapies for rare diseases like thyroid eye disease, reported a first-quarter loss of $0.90 per share (better than expected) and a 95.8% year-over-year revenue increase. Analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and an average price target of $38.79.
(VRDN) Volatility Zones as Tactical Triggers
This article provides an AI-driven analysis of Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting neutral readings in shorter time horizons and a weak bias in the long term. It identifies an exceptional short setup with a significant risk-reward ratio and outlines three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each tailored to different risk profiles. The analysis includes specific entry zones, targets, and stop-loss levels based on multi-timeframe signal analysis.
How Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors
Viridian Therapeutics reported positive topline results from its Elegrobart REVEAL-1 phase III trial for Graves' ophthalmopathy, planning a Biologics License Application in early 2027. This, alongside the recent LUMVOA approval, strengthens the company's position in the autoimmune eye disease market, despite continued unprofitability and shareholder dilution. Investors face execution risk regarding commercial uptake and whether it can support the current valuation, with fair value estimates varying widely.
How Positive Elegrobart REVEAL-1 Phase III Data Could Impact Viridian Therapeutics (VRDN) Investors
Viridian Therapeutics reported positive topline results from its Elegrobart REVEAL-1 phase III trial for Graves' ophthalmopathy, moving towards a Biologics License Application in early 2027. This development, alongside the approval of LUMVOA, strengthens Viridian's position in the autoimmune eye disease market and validates its investment narrative. While the company remains unprofitable and has diluted shareholders, the recent news significantly bolsters its growth prospects and commercial catalysts despite some market optimism already being priced in.
Price to earnings forward of Viridian Therapeutics, Inc. – LSE:0K1R
This article provides the "Price to earnings forward" value for Viridian Therapeutics, Inc. (LSE:0K1R). The core data presented is a single numerical value for this financial metric, alongside its change and percentage change. The article focuses solely on this specific financial data point for the company.
Viridian Therapeutics Inc (VRDN) Institutional Confidence
Viridian Therapeutics Inc (VRDN) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 8.27% quarter-over-quarter, reaching 112.73%. Steven Cohen is the largest institutional shareholder, holding 365.59K shares and increasing his holdings by 9.44%.
Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides an incomplete revenue breakdown for Viridian Therapeutics Inc (VRDN), stating that much of the relevant data has not yet been disclosed by the company. It does, however, show a regional revenue figure for the United States at $70.85 million with a 0.00% proportion, indicating a potential data entry issue or lack of comprehensive data. The article also provides current stock information for VRDN.
VRDN|Viridian Therapeutics Inc|Price:19.890|Chg%:+0.380
Viridian Therapeutics Inc. (VRDN) is a biopharmaceutical company specializing in developing medicines for rare diseases, currently focusing on Thyroid Eye Disease (TED) with two global Phase 3 trials for veligrotug and two for VRDN-003. The company is also advancing a portfolio of neonatal Fc receptor inhibitors for autoimmune diseases. Shares are trading at $19.890, up 1.95%, with a market cap of $2.04 billion.
Viridian Therapeutics Inc (VRDN) Income Statement
This article provides a detailed quarterly and annual income statement for Viridian Therapeutics Inc (VRDN), covering various financial metrics from total revenue to basic and diluted earnings per share. It also includes frequently asked questions about how to interpret these statements and key metrics for analyzing the stock.
VRDN|Viridian Therapeutics Inc|Price:19.270|Chg%:+0.010
This article provides a comprehensive stock analysis of Viridian Therapeutics Inc (VRDN) by TradingKey. It highlights the company's strong fundamentals, significant growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. The analysis notes high institutional ownership, a "Buy" rating from multiple analysts with a target price of $35.33, and ongoing clinical trials for serious diseases like thyroid eye disease.
Viridian Therapeutics, Inc. Revenue Breakdown – NASDAQ:VRDN
Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported its revenue breakdown. In the last year, the company generated $70.85 million USD, with Monoclonal Antibody being its top-performing segment. The United States was the primary contributor to this revenue.
Viridian Therapeutics stock trades around recent lows as cash runway and thyroid eye trial data shap
Viridian Therapeutics (VRDN) stock is trading around recent lows, influenced by its cash runway and upcoming thyroid eye disease trial data. The biotech company is advancing its lead investigational product for thyroid eye disease, having reported positive mid-stage clinical trial data, but faces challenges managing its cash burn rate and potential future dilution from financing activities. Investors are closely watching the balance between pipeline progress and financing needs, with valuation sensitive to clinical trial outcomes and regulatory progress.
Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Viridian Therapeutics Inc (VRDN), highlighting its current valuation score of 6.83, which ranks it 295 out of 386 in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -4.82 and mentions that relevant data for P/B, P/S, and P/CF have not yet been disclosed by the company.
Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
Wells Fargo analyst Derek Archila maintained a Buy rating on Viridian Therapeutics (VRDN) with a price target of $31.00. This reaffirmation comes as the company reported a quarterly revenue of $141 thousand and a GAAP net loss of $104.9 million, alongside positive corporate insider sentiment with recent share purchases. The stock currently holds a Strong Buy consensus among analysts, with an average price target of $33.91.
Viridian Therapeutics (VRDN) Stock Analysis: A Biotech Gem with Nearly 95% Upside Potential
Viridian Therapeutics (VRDN) is identified as a promising biotechnology company with significant growth potential, particularly in developing treatments for thyroid eye disease (TED) and Graves’ disease. Despite typical biotech financial metrics showing early-stage development, analysts forecast a nearly 95% upside potential, with an average target price of $36.13. The company's strong pipeline, positive analyst sentiment, and strategic focus on innovative therapies position it as a compelling opportunity for investors willing to undertake the inherent risks of the biotech sector.
Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31
Wells Fargo has reiterated its Buy rating for Viridian Therapeutics (VRDN.US) and maintained its target price at $31. This indicates a continued positive outlook from the firm regarding the company's stock performance.
